Insider Transactions in Q4 2020 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2020
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
405
+15.65%
|
$6,075
$15.02 P/Share
|
|
Dec 31
2020
|
Qasim Rizvi Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,161
-29.45%
|
$36,737
$17.67 P/Share
|
|
Dec 31
2020
|
Qasim Rizvi Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,337
+50.0%
|
-
|
|
Dec 31
2020
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,297
-29.45%
|
$22,049
$17.67 P/Share
|
|
Dec 31
2020
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,404
+50.0%
|
-
|
|
Oct 12
2020
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
99,330
-46.88%
|
$2,085,930
$21.02 P/Share
|
|
Oct 12
2020
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
150,700
-100.0%
|
$3,164,700
$21.02 P/Share
|
|
Oct 12
2020
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
150,700
+50.0%
|
$150,700
$1.59 P/Share
|
|
Oct 09
2020
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
670
-0.32%
|
$14,070
$21.0 P/Share
|
|
Oct 09
2020
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
872
-100.0%
|
$18,312
$21.0 P/Share
|
|
Oct 09
2020
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+50.0%
|
$872
$1.59 P/Share
|